Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug aims to wake up transplanted kidneys faster

NCT ID NCT07020832

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 2 times

Summary

This study tests a drug called pegcetacoplan in 320 adults who are getting a kidney transplant from a deceased donor and are at high risk for delayed graft function (when the kidney takes a while to start working). The goal is to see if the drug helps the kidney work sooner and reduces the need for dialysis after transplant. Participants will receive either pegcetacoplan or a placebo, and their kidney function will be tracked for up to a year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Started

May 2026

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged at least 18 years 2. Have end-stage kidney disease and be on the waiting list for a kidney transplant from a deceased donor. 3. Be on dialysis at the time of your transplant and produce very little urine (less than 200 mL per day equivalent to ≤1 cup). You must have been on dialysis for at least 3 months. 4. Be receiving your first or second kidney transplant from a deceased donor. If this is your second transplant: 1. It cannot be due to a serious infection or a serious blood clot in your previous transplant. 2. Your calculated Panel Reactive Antibody (CPRA) level must be below 50%. 5. Be getting a donor kidney that meets the study's specific requirements. 6. Be at low to medium risk of transplant rejection, and be scheduled to receive: 1. A medication called ATG as part of your transplant procedure. 2. Steroids (corticosteroids) as part of your treatment at the time of screening. 3. A medication called tacrolimus (or a similar drug) after your transplant, according to usual medical practice. 7. Have received certain vaccines before starting the study treatment, specifically: 1. Pneumococcal (S. pneumoniae) 2. Meningococcal (N. meningitidis types A, C, W, Y, and B) 3. Haemophilus influenzae type B If you haven't had these vaccines, you may still qualify to be part of the study, provided your doctor plans to administer preventive antibiotics until vaccination can be given per protocol, and with notification to the sponsor. Exclusion Criteria: 1. Have taken part in another medical research study or used an experimental drug, treatment, or device in the past 30 days (or longer, depending on the drug). 2. Have recently used certain medications that affect the immune system, such as rituximab, belimumab, or other approved complement-blocking drugs. 3. Weigh less than 20kg or more than 120kg at screening. 4. Have or had recently had any of the following infections: 1. Hepatitis B or Hepatitis C (unless treated and no longer active). 2. HIV (human immunodeficiency virus) at any time. 5. Have had cancer in the past 5 years, unless it was: 1. A small, treated skin cancer (like basal or squamous cell), or 2. A very small kidney cancer that was found early and treated. 6. Have received any other organ transplant (except for one previous kidney transplant), or are scheduled for a transplant involving more than one organ.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Deceased donor kidney transplant are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

    São Paulo, 01323-001, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.